ZGNX earnings call for the period ending June 30, 2020.
News & Analysis: Zogenix
ZGNX earnings call for the period ending March 31, 2020.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
Zogenix's recent slump presents a questionable buying opportunity.
ZGNX earnings call for the period ending December 31, 2019.
Zogenex's lead drug candidate may soon be approved to treat the same patients targeted by GW Pharmaceutials' Epidiolex.
Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.
Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.
ZGNX earnings call for the period ending September 30, 2019.
Surprisingly, it had nothing to do with the pharma company's earnings report.